Immunogenicity of Twinrix in older adults: a critical analysis

Expert Rev Vaccines. 2003 Feb;2(1):9-14. doi: 10.1586/14760584.2.1.9.

Abstract

Twinrix (GlaxoSmithKline Biologicals, Rixensart, Belgium) is the first combined vaccine to provide protection against both hepatitis A and B. This review presents a critical analysis of antibody responses stratified by age following vaccination with Twinrix in 264 adults aged above 40 years. A month after completion of a 0-, 1-, 6-month vaccination schedule with Twinrix, a good response was observed for both anti-HAV and anti-HBs serum antibodies, suggesting that is an effective vaccine in older adults.

Publication types

  • Meta-Analysis

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Clinical Trials as Topic
  • Comorbidity
  • Databases, Factual
  • Female
  • Hepatitis A Antibodies / biosynthesis
  • Hepatitis A Antibodies / blood
  • Hepatitis A Vaccines / immunology*
  • Hepatitis B Antibodies / biosynthesis
  • Hepatitis B Antibodies / blood
  • Hepatitis B Vaccines / immunology*
  • Humans
  • Immunization Schedule
  • Male
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • Retrospective Studies
  • Vaccination
  • Vaccines, Combined / immunology*

Substances

  • Hepatitis A Antibodies
  • Hepatitis A Vaccines
  • Hepatitis B Antibodies
  • Hepatitis B Vaccines
  • Vaccines, Combined
  • twinrix